Newpath Partners

Newpath Partners is a venture capital firm based in Boston, Massachusetts, specializing in multi-stage investments within the life sciences and healthcare sectors. Established in 2018, the firm operates with a distinctive thesis that extends beyond merely funding companies; it actively engages in their creation from the ground up. Newpath Partners collaborates closely with leading academic scientists to translate groundbreaking scientific discoveries into transformative therapies, addressing significant unmet medical needs.

The firm's investment strategy is centered on breakthrough biology platforms, including gene editing, regenerative medicine, and innovative therapeutics. Newpath Partners is known for its deep involvement in the early stages of company formation, often acting as a founding investor. They deploy capital across various stages, from pre-seed and seed rounds to Series A, Series B, and growth equity investments, demonstrating a commitment to supporting companies throughout their development lifecycle.

Newpath Partners has built a substantial portfolio of companies focused on advancing critical areas of biotechnology and medicine. Notable investments include companies like Neumora Therapeutics, which focuses on neuroscience innovations; Prime Medicine, a leader in gene editing technologies; Chroma Medicine, specializing in epigenetics therapeutics; and Myeloid Therapeutics (now CREATE Medicines), which develops myeloid cell-based immunotherapy and in vivo immune programming therapies. The firm's portfolio reflects its dedication to high scientific originality and the potential for significant impact on patient care.

The team at Newpath Partners comprises highly specialized professionals with deep scientific and medical expertise. Key individuals include Founder and Managing Partner Thomas Cahill, M.D., Ph.D., Co-Founder Daniel Yadegar, M.D., and Investment Officer Tom Thomas, Ph.D. Their collective background in both science and business enables the firm to provide not only capital but also strategic guidance and operational support, fostering close collaborations with founders and academic partners to drive innovation and success in the life sciences arena.